Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting
A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated NCCN guidelines now recommending toripalimab plus gemcitabine/cisplatin as category 1 first-line therapy for recurrent/metastatic (R/M) disease based on the JUPITER-02 trial results showing significantly improved 4-year overall survival (OS) rates of 48% vs 27.7% with chemotherapy alone, while emphasizing that treatment decisions should consider patient-specific factors, such as Epstein-Barr virus status, prior treatments, and comorbidities, alongside nonpatient factors, including drug accessibility, need for rapid response, and capacity to manage immune-related adverse events.
Video content above is prompted by the following:
- Please give a general overview of treatment strategies for recurrent NPC.
- Please refer to and note the updated NCCN guidelines.
- Please discuss a treatment approach for the recurrent disease in this patient case.
- Review the most recent update from JUPITER-02 evaluating toripalimab plus gemcitabine/cisplatin in R/M NPC.
- What are your thoughts on the 4-year OS data?
- What patient/non–patient specific factors stand out to you from the trial that would inform treatment decisions in real-world practice?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
